Prognostic factors in renal cell carcinoma

Scandinavian Journal of Surgery

Volumn 93, Issue 2, 2004, Pages 118-125

  Ljungberg, Börje ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Metastases; Prognosis; Renal cell carcinoma; Therapy; Tumour progression

Indexed keywords

TUMOR MARKER;

ANGIOGENESIS; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; NEPHRECTOMY; PROGNOSIS; REVIEW;

EID: 3242690576     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690409300206     Document Type: Review

References (92)

1. Thrasher JB, Paulson DF: Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-262
2. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA: Adoptive cellular therapy. Semin Oncol 2000;27:221-233
3. Favrot MC, Puisieux I: Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols. Adv Exp Med Biol 1998;451:539-541
4. Hoos A, Levey DL: Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines 2003;2:369-379
5. Childs R, Chernoff A: Regression of metastatic renal-cell carcinoma. NEJM 2000;343:750-758
6. Jonas D, Thoma B, Beckert H, Weber W: The value of morphological prognostic criteria in the assessment of renal cell carcinoma. Urol Int 1985;40:48-154
7. Thönes W, Störkel S, Rumpelt HJ: Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125-143
8. Kovacs G, Wilkens L, Papp T de Riese W: Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Nat Cancer Inst 1989;81:527-530
9. Kovacs G: Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993;62:89-124
10. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, Vandenberg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-133
11. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K: Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-989
12. Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11:71-77
13. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-291
14. Ljungberg B, Alamdari FI, Stenling R, Roos G: Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 1999;36:565-569
15. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS: Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997;21:621-635
16. Mancilla-Jimenez R, Stanley RJ, Blath RA: Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976;38:2469-2480
17. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ: Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000; 89:604-614
18. Crotty TB, Farrow GM, Lieber MM: Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995;154:964-967
19. Srigley JR, Eble JN: Collecting duct carcinoma of kidney. Semin Diagn Pathol 1998;15:54-67
20. Schullerus D, Herbes J, Chudek J, Kanamaru H Kovacs G: Loss of heterozygosity at chromosomes 8p, 9p and 14q is associated with stage and grade of nonpapillary renal cell carcinomas. J Pathol 1997;183:151-155
21. Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F: Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002;167:1464-1468
22. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H: Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998;153:1467-1473
23. Childs RW: Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit Rev Immunol 2001;21:191-203
24. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF: Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer 1971;28: 1165-1177
25. Ljungberg B, Iranparar Alamdari F, Rasmuson T and Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. Br J Urol 1999;84:405-411
26. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-993
27. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H: Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91:354-361
28. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR: Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995;45:34-40; discussion 40-41
29. Javidan J, Stricker HJ, Tamboli P, Amin MB, Peabody JO, Deshpande A, Menon M, Amin MB: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277-1281
30. Sobin LH, Wittekind CH, Eds: International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th Ed. New York: 2002:193-195
31. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS: TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003;169:899-903; discussion 903-904
32. Fiori E, De Cesare A, Galati G, Bononi M, D'Andrea N, Barbarosos A, Izzo L, Bolognese A: Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma. J Exp Clin Cancer Res 2002;21:229-232
33. Ljungberg B, Stenling R, Österdahl B, Farrelly E, Aberg T and Roos G: Vein invasion in renal cell carcinoma: impact on metastatic behaviour and survival. J Urol 1995;154:1681-1684
34. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003;169:909-916
35. Uzzo RG, Cherullo EE, Myles J, Novick AC: Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 2002;167:2392-2396
36. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS: Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 2003;170:768-772; discussion 772
37. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma: N Engl J Med 1996;335:865-875
38. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C: Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76:2543-2549
39. Ficarra V, Righetti R, Pilloni S, D'amico A, Maffei N, Novella G, Zanolla L, Malossini G, Mobilio G: Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 2002;41:190-198
40. Ruiz JL, Hernandez M, Martinez J, Vera C, Jimenez-Cruz JF: Value of morphometry as an independent prognostic factor in renal cell carcinoma. Eur Urol 1995;27:54-57
41. Carducci MA, Piantadosi S, Pound CR, Epstein JI, Simons JW, Marshall FF, Partin AW: Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 1999;53:44-49
42. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-2400
43. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, Zincke H: A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003;170:2225-2232
44. Ljungberg B, Mehle C, Stenling R, Roos G: Heterogeneity in renal cell carcinoma and its impact on prognosis - a flow cytometric study. Br J Cancer 1996;74:123-127
45. Di Silverio F, Casale P, Colella D, Andrea L, Seccareccia F, Sciarra A: Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 2000;88:835-843
46. Sringley JR, Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM: Current prognostic factors - renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:994-996
47. Larsson P, Roos G, Stenling R, Ljungberg B: Proliferating cell nuclear antigen expression in renal cell carcinoma - prognostic implications. Scand J Urol Nephrol 1996;30:445-450
48. Larsson P, Roos G, Stenling R, Ljungberg B: Proliferation of human renal cell carcinoma studied with in vivo iododeoxy-uridine labelling and immunohistochemistry. Scand J Urol Nephrol 21994;8:135-140
49. Rioux-Leclercq N, Epstein JI, Bansard JY, Turlin B, Patard JJ, Manunta A, Chan T, Ramee MP, Lobel B, Moulinoux JP: Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001;32:1209-1215
50. Renshaw AA, Loughlin KR, Dutta A: Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod Pathol 1998;11:96396-6
51. Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, Guille F, Ramee MP, Lobel B: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55: 501-505
52. Hedberg Y, Ljungberg B, Roos G, Landberg G: Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 2003;88:1417-1423
53. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjänen K, Kosma VM: Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999; 80:2001-2007
54. Migita T, Oda Y, Naito S, Tsuneyoshi M: Low expression of p27 (Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002;94:973-979
55. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G: Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 2002;102:601-607
56. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
57. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U, Maher ER, Grone HJ, Eckardt KU: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61:5215-5222
58. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-347
59. Ljungberg B, Jacobsen J, Häggström S, Rasmuson T, Lindh G, Grankvist K: Tumor Vascular Endothelial Growth Factor (VEGF) mRNA in relation to serum VEGF protein levels and tumor progression in human renal cell carcinoma. Urol Res 2003;31:335-340
60. Moch H, Sauter G, Gasser TC, Buchholz N, Bubendorf L, Richter J, Jiang F, Dellas A, Mihatsch MJ: p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997;25 Suppl 1:S25-30
61. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S: Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615-620
62. Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, Landberg G: p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol 2001;35:15-20
63. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK: Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol 1999;162:610-613
64. Ljungberg B, Österdahl B, Mehle C: Clinical significance of nm23 expression in renal cell carcinoma. Urol Res 1999;27:103-107
65. Hofmockel G, Riess S, Bassukas ID, Dammrich J: Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. Eur Urol 1997;31:478-484
66. Stumm G, Eberwein S, Rostock-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R: Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996:20;69:17-22
67. Rasmuson T, Grankvist K, Ljungberg B: Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer 1997;75:1674-1677
68. Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S: MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999;83:743-747
69. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B: Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44:226-232
70. Abou El Fettouh HI, Cherullo EE, El-Jack M, Al Maslamani Y, Novick AC: Sporadic renal cell carcinoma in young adults: presentation, treatment, and outcome. Urology 2002;60:806-810
71. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA: Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170:1742-1746
72. Pantuck AJ, Zisman A, Rauch MK, Belldegrun A: Incidental renal tumors. Urology 2000;56:190-196
73. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-1095
74. Ljungberg B, Landberg G, Alamdari F: Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000;34:246-251
75. Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C, Rehak P, Pummer K, Hubmer G: Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology 2003;62:1024-1028
76. Ljungberg B, Grankvist K, Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995; 76:1435-1439
77. Roosen JU, Engel U, Jensen RH, Kvist E, Schou G: Renal cell carcinoma: prognostic factors. Br J Urol 1994;74:160-164
78. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F: Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-2458
79. Rasmuson T, Grankvist K, Roos G, Ljungberg B: Neuroendocrine differentiation in renal cell carcinoma - evaluation of chromogranin A and neuron-specific enolase. Acta Oncol 1999;38:623-628
80. Ljungberg B, Rasmuson T, Grankvist K: Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 1992;21:160-163
81. Ljungberg B Grankvist K, Ljungberg B, Rasmuson T: Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 1997;74:233-236
82. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, EORTC Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-970
83. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659
84. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM: Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol 1999;35:197-203
85. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H: Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002;74:1653-1657
86. Tanguay S, Pisters LL, Lawrence DD, Dinney CP: Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 1996;155:26-29
87. Schlichter A, Wunderlich H, Junker K, Kosmehl H, Zermann DH, Schubert J: Where are the limits of elective nephron-sparing surgery in renal cell carcinoma? Eur Urol 2000;37:517-520
88. Fergany AF, Hafez KS, Novick AC: Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163:442-445
89. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P: A post-operative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-67
90. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-1657
91. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-4566
92. Griffiths DF, Verghese A, Golash A, Kynaston HG, Matthews PN, Hart AJ, Court JB:. Contribution of grade, vascular invasion and age to outcome in clinically localized renal cell carcinoma. BJU Int 20021;90:26-31